Fig. 3From: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinomaIcaritin-based nanomedicines for inducing ICD in advanced HCC. a PLGA-PEG-AEAA NPs were prepared by a solvent displacement technique to load icaritin and DOX. b The produced NPs displayed targeted delivery of icaritin and DOX, and efficiently improved the anti-HCC effect by remodeling the immunosuppressive tumor microenvironment and triggering a robust immune memory response. Reprinted with the permission from Ref. [45] Copyright © 2020, American Chemical Society. ICD immunogenic cell death, HCC hepatocellular carcinoma, PLGA poly lactic-co-glycolic acid, PEG poly ethylene glycol, mPEG monomethoxy poly ethylene glycol, AEAA aminoethyl anisamide, DOX doxorubicin, HMGB1 high mobility group box 1, ER estrogen receptor, CRT calreticulin, LC3-II microtubule-associated protein light chain 3 II, DC dendritic cell, IFN-γ interferon-γBack to article page